Welcome to our dedicated page for Seagen news (Ticker: sgen), a resource for investors and traders seeking the latest updates and insights on Seagen stock.
Seagen Inc. (SGEN) is a comprehensive news resource for this biotechnology leader in antibody-drug conjugate (ADC) cancer therapies. Track official updates on clinical trials, regulatory milestones, and strategic partnerships that drive innovation in oncology treatment.
This page consolidates Seagen's verified announcements including Adcetris® developments, pipeline progress for therapies like SGN-CD19A and SEA-CD40, and collaborations with industry partners like Takeda and AbbVie. Investors gain timely access to earnings reports, research breakthroughs, and market-moving updates.
All content is curated to meet the needs of both medical professionals and financial stakeholders. Bookmark this page for direct access to Seagen's latest FDA submissions, trial results, and partnership expansions – essential information for informed decision-making in biotech investments.
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) has completed the acquisition of Seagen Inc. (NASDAQ: SGEN) for $43 billion, solidifying its position as a leading oncology company. The acquisition brings Seagen's world-leading Antibody-Drug Conjugate (ADC) technology and four in-line medicines to Pfizer's oncology portfolio. Dr. Albert Bourla, Pfizer's Chairman and CEO, emphasizes the company's commitment to delivering breakthrough treatments for cancer, with Oncology expected to be a significant growth driver for Pfizer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Pfizer Inc. (PFE) is set to close the acquisition of Seagen Inc. (SGEN) on December 14, 2023, after receiving all required regulatory approvals. The company also announced changes in its commercial organization to incorporate Seagen and improve focus, speed, and execution. Pfizer will host an analyst and investor call to discuss the acquisition, new commercial organization, and provide full-year 2024 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Seagen Inc. (NASDAQ: SGEN) announced encouraging results from a Phase 2 study evaluating ADCETRIS in combination with nivolumab and standard chemotherapy agents as first-line treatment for early and advanced stage classical Hodgkin lymphoma. The investigational regimen showed a clinically meaningful progression-free survival rate, favorable clinical outcomes, and a consistent safety profile, with no new safety signals observed. The study demonstrated an overall response and complete response rate of 98% and 93% respectively in early-stage cHL patients, and an overall response and complete response rate of 95% and 89% respectively in advanced-stage cHL patients. The PFS rate at 24 months for advanced-stage cHL patients was 88%. ADCETRIS has been a proven foundation of care for CD30-expressing lymphomas globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
Rhea-AI Summary
Seagen Inc. (Nasdaq: SGEN) announced positive data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with ado-trastuzumab emtansine for patients with HER2-positive breast cancer. The combination showed a significant improvement in progression-free survival and objective response rate, with manageable adverse events. TUKYSA is already approved by the FDA for third-line metastatic HER2-positive breast cancer, and the trial results reinforce its clinical activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
-
Rhea-AI Summary
Seagen Inc. (SGEN) and Astellas Pharma Inc. (4503) announced that the FDA accepted for priority review a supplemental Biologics License Application for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The combination significantly extended overall survival and progression-free survival vs standard platinum-containing chemotherapy. If approved, it would be the first and only antibody-drug conjugate plus PD-1 inhibitor treatment alternative to chemotherapy in this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
-
Rhea-AI Summary
Seagen Inc. presented Phase 2 data for ADCETRIS in combination with pembrolizumab in non-small cell lung cancer and melanoma. The combination showed objective response rates of 8% and 14% in NSCLC, and 18% and 22% in melanoma. Disease control rates were 67% and 72% in NSCLC, and 71% and 80% in melanoma. The safety profile was consistent with previous studies. Preclinical data was also presented for SGN-35T, a novel ADC with potential for improved tolerability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
Rhea-AI Summary
Seagen Inc. (NASDAQ: SGEN) announced that updated Phase 2 data for ADCETRIS in combination with nivolumab in early and advanced stage classical Hodgkin lymphoma will be presented at the 65th American Society of Hematology (ASH) Annual Meeting. The data will include 12- and 24-month progression free survival rates. Additionally, preclinical data for the investigational antibody-drug conjugate SGN-35C will also be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
-
Rhea-AI Summary
Seagen Inc. reported record net product sales of $571 million in 3Q23, a 33% increase over 3Q22. PADCEV® in combination with Keytruda® demonstrated a near doubling of median overall survival in first-line metastatic urothelial cancer. The proposed Pfizer transaction is on-track to close in late-2023 or early-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
-
Rhea-AI Summary
Seagen Inc. and Genmab A/S announced positive results from the Phase 3 innovaTV 301 trial, showing that TIVDAK demonstrated a 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients compared to chemotherapy. TIVDAK also showed significant improvements in overall survival, progression-free survival, and objective response rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Seagen and Astellas announce positive results from Phase 3 clinical trial for enfortumab vedotin plus pembrolizumab in urothelial cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Seagen Inc